← Human Trials & Peer-Reviewed Studies
Mucosal glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide cell numbers in the super-obese human foregut after gastric bypass
Plain-language guide to PMID 26143297 (2015): randomized controlled trial study of GIP (Gastric Inhibitory Polypeptide).
Key Facts
- PMID
- 26143297
- Journal
- Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Nergård BJ et al. (7 authors)
- DOI
- 10.1016/j.soard.2015.03.021
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.
To study the effects of laparoscopic RYGB on enteroendocrine cells.
Why It Was Studied
Super-obesity, a body mass index>50 kg/m(2), is difficult to treat.
Many studies have focused on the anatomic changes of the intestines; the physiologic background is not clearly identified.
Who Took Part
By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.
Eighteen nondiabetic patients were drawn from the present study (NCT 01514799), randomizing between biliopancreatic (BP) limbs of either 60 cm (BP60) or 200 cm (BP200).
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got GIP (Gastric Inhibitory Polypeptide) and who got the comparison, which limits bias.
University-affiliated, high-volume bariatric surgery center.
Pouch and jejunal biopsies were obtained intraoperatively and using endoscopy at 12 months.
Mucosal height and density of hormone-producing cell populations were assessed and mRNA expression measured with real-time polymerase chain reaction.
What Was Measured
Many studies have focused on the anatomic changes of the intestines; the physiologic background is not clearly identified.
Topics PubMed links to this paper include Biomarkers, Blood Glucose, Body Mass Index, Cell Count, Gastric Bypass, Gastric Inhibitory Polypeptide and Gastric Mucosa.
Author keywords: Enterohormones, GIP, GLP-1, Incretins and Superobesity.
What This Means in Plain Language
The paper is a randomized study of GIP (Gastric Inhibitory Polypeptide).
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2015 (Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery), a journal based in United States.
More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.
Our Notes on the Compound
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.